In a joint press release, Celularity Inc. and DefEYE, Inc., a newly established ophthalmic product and technology company, have announced a strategic partnership. As part of the terms of the agreement, Celularity has executed an exclusive license and pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12 million Series Seed Preferred Equity funding round.

DefEYE says it expects to use the proceeds of its Series Seed Preferred Equity round to launch and scale a portfolio of decellularized biologic solutions for eye care, including: single and tri-layer decellularized amniotic basement membrane, Biovance and Biovance 3L Ocular, respectively; Interfyl, a flowable human connective tissue derived from the chorionic plate; and collaborative research and development for future commercial products.

Additionally, Celularity granted DefEYE an exclusive sublicense to its ophthalmic biologics portfolio, which includes Biovance, Biovance 3L, Interfyl, and CentaFlex. Celularity will be the exclusive contract manufacturer for DefEYE’s portfolio of ophthalmic biologics solutions, according to the press release. OM